Chimeric antigen receptor‐modified macrophages trigger systemic anti‐tumour immunity. Issue 3 (4th December 2020)

• Record Type: Journal Article
• Authors: Niu, Zhiyuan; Chen, Guanxu; Chang, Wei; Sun, Pengyang; Luo, Zhixia; Zhang, Huiyong; Zhi, Lingtong; Guo, Changjiang; Chen, Han; Yin, Meichen; Zhu, Wuling
• Is Part Of: Journal of pathology. Volume 253:Issue 3(2021)
• Page Start: 247
• Page End: 257
• Publication Date: 2020-12-04
• Subjects: breast cancer -- adoptive cell therapy -- macrophage; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.5585
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: Preliminary results and emerging data have shown that lipid droplet high (LD hi ) immunosuppressive cells accumulate in tumour tissues. By tracking and phenotypic profiling of LD hi cells, we find that LD hi CD19 +, LD hi CD11b +, and LD hi Ly6G + immune cell populations appear in the spleen, thymus, and tumour tissues in a syngeneic tumour model. Using a contact‐dependent reporter system, we discover a LD hi CCR7 hi immunosuppressive cell population that migrates from tumour tissues to the spleen and thymus. Hence, we engineered a family of chimeric antigen receptor‐modified macrophages (CAR‐Ms) that direct macrophages to CCR7‐positive cells and show that the cytosolic domain from Mer receptor tyrosine kinase (MerTK) triggers tumour cell cytotoxicity by the CAR‐Ms. In vivo, CCR7‐targeted CAR‐Ms suppressed tumour growth and prolonged survival by preventing metastasis and by inducing systemic anti‐tumour immunity through retarding the migration of LD hi CCR7 hi immunosuppressive cells from tumour tissues to distal immune organs, indicating an important role for CCR7 in tumour cell‐induced immune tolerance. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.